Skip to main content

Stratagene s PCR Reagents Infringe Third Wave s Invader Tech; Jury to Deliberate Damages

Click  here for an updated version of this article.

NEW YORK, Sept. 1 (GenomeWeb News) - A jury has determined that Stratagene's quantitative PCR and RT-PCR reagents infringe two patents held by Third Wave Technologies as part of its Invader technology, Stratagene said today.

 

The jury, appointed by the United States District Court for the Western District of Wisconsin, found that certain embodiments of Stratagene's FullVelocity technology violate Third Weave's US patents Nos. 6,090,543 and 6,348,314. The jury will now hear arguments with respect to damages.

 

Third Wave filed the suit  last September. At the time, Stratagene said certain embodiments of its FullVelocity technology are not covered by Third Wave's patents.

 

In May, Stratagene countersued Third Wave claiming that Third Wave infringes patents that cover its FullVelocity technology. Stratagene's patents are USpatent Nos. 6,350,580; 6,528,254; 6,548,250; 6,589,743; and 6,893,819.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.